Načítá se...
LONG-TERM TREATMENT WITH PEGVISOMANT AS MONOTHERAPY IN PATIENTS WITH ACROMEGALY: EXPERIENCE FROM ACROSTUDY
OBJECTIVE: To evaluate use of pegvisomant, a GH receptor antagonist, as monotherapy in ACROSTUDY, a global safety surveillance study set in 14 countries (373 sites). METHODS: A descriptive analysis of safety, magnetic resonance imaging (MRI) reading and treatment outcomes in 710 subjects who receive...
Uloženo v:
| Vydáno v: | Endocr Pract |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4618502/ https://ncbi.nlm.nih.gov/pubmed/25370326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4158/EP14330.OR |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|